fezolinetant (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Menopausal Vasomotor Symptoms

Pending FDA approval for moderate-to-severe vasomotor symptoms (VMS) associated with menopause

Next:

Pharmacology

Mechanism of Action

Nonhormonal selective neurokinin 3 (NK3) receptor antagonist

Blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin/dynorphin (KNDy) neuron to moderate neuronal activity in the hypothalamus, and thereby reduces frequency and severity of vasomotor symptoms

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.